4-羟基-2-氧代-1H-喹啉-3-甲酰胺 | 139713-59-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-羟基-2-氧代-1H-喹啉-3-甲酰胺
• 英文名称: 4-hydroxy-2-oxo-1,2 dihydroquinoline-3-carboxamide
• 英文别名: 4-hydroxy-2-quinolone-3-carboxamide；4-Hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamide；4-hydroxy-2-oxo-1H-quinoline-3-carboxamide
• CAS: 139713-59-0
• 化学式: C₁₀H₈N₂O₃
• 分子量: 204.185
• InChiKey: YOLDGFOLHQULBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  92.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  三氯氧磷 、 4-羟基-2-氧代-1H-喹啉-3-甲酰胺 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Koller; Ruppersberg; Strang, Monatshefte fur Chemie, 1929, vol. 52, p. 60,67

  摘要：

  DOI：
• 作为产物：
  描述：

  2,4-dioxo-3H-quinoline-3-carboxylic acid 在 氨 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 以91%的产率得到4-羟基-2-氧代-1H-喹啉-3-甲酰胺
  参考文献：
  名称：

  4-Hydroxy-2-quinolones. 4. selection of the optimum path for synthesis of n-r-substituted 4-hydroxy-2-quinolone-3-carboxylic acid amides

  摘要：

  DOI：

  10.1007/bf00475252

文献信息

• 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS
  申请人：Pettersson Lars

  公开号：US20130203703A1

  公开（公告）日：2013-08-08

  The present invention relates to compounds which are 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides, their thieno-pyridone analogs, and prodrugs thereof. This invention specifically relates to such derivatives containing an N-hydrogen in the carboxanilide moiety and which exhibit modulating activity towards the aromatic hydrocarbon receptor (AhR), and, specifically, also to prodrugs thereof. The present invention also relates to use of said compounds as a medicament, and for the treatment of cancer, autoimmune disorders and other disorders with an immunological component, and a pharmaceutical composition comprising one or more of said compounds and a method of treatment.

  本发明涉及1,2-二氢-4-羟基-2-氧代-喹啉-3-羧酰苯胺类化合物、其噻吩-吡啶酮类似物以及它们的前药。本发明具体涉及含有羧酰苯胺基团中的N-氢的衍生物，它们表现出对芳香族碳氢受体（AhR）的调节活性，以及它们的前药。本发明还涉及所述化合物作为药物的用途，用于治疗癌症、自身免疫性疾病以及其他具有免疫学成分的疾病，以及一种包含一种或多种所述化合物的药物组合物和一种治疗方法。
• TREATMENT OF CROHN'S DISEASE WITH LAQUINIMOD
  申请人：Teva Pharmaceutical Industries Ltd.

  公开号：EP2458992A1

  公开（公告）日：2012-06-06
• SUBSTITUTED 2-OXO- AND 2-THIOXO-DIHYDROQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS
  申请人：Grünenthal GmbH

  公开号：EP2609086B1

  公开（公告）日：2015-02-25
• Treatment of Crohn's disease with laquinimod
  申请人：Tarcic Nora

  公开号：US20110027219A1

  公开（公告）日：2011-02-03

  This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease.
• USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNF THERAPY
  申请人：Tarcic Nora

  公开号：US20130203807A1

  公开（公告）日：2013-08-08

  This application provides for a method of treating a human patient afflicted with anti-TNFα refractory Crohn's disease, of treating a human patient afflicted with non-fibrostenotic Crohn's disease, and of treating a human patient whose Crohn's disease had not been surgically treated, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient. This application also provides for a method of inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease comprising periodically administering to the patient an amount of laquinimod effective to induce or maintain clinical remission in the patient, which amount of laquinimod is less than 0.5 mg/day.